Sensorium Unveils Novel Anxiety Drug, Fortifies Leadership for Clinical Push

CAMBRIDGE, Mass. – May 27, 2026 – Clinical-stage biotechnology company Sensorium Therapeutics today announced significant strides in its mission to develop new treatments for anxiety disorders, a condition that affects millions globally. The company will present preclinical data and the design of its Phase 1a study for its lead drug candidate, SNTX-2643, at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach.

In a concurrent move signaling a major step-up in its clinical capabilities, Sensorium also announced the appointment of industry veteran Dr. Cole Brown as its new Chief Medical Officer and the formation of a high-profile Clinical Advisory Board composed of world-renowned experts in psychiatry and drug development.

These developments highlight the company's multi-pronged strategy to tackle the significant unmet needs in mental health, combining novel science with deep clinical and strategic expertise. SNTX-2643 is being developed for anxiety disorders, with an initial focus on social anxiety and generalized anxiety disorder.

"Behind every statistic on anxiety is a person whose life has been narrowed by it, and far too many remain underserved by the treatments available today," said Jacob Hooker, Ph.D., Co-Founder and Chief Executive Officer of Sensorium Therapeutics. "SENS-01 reflects our commitment to changing that through a mechanistically differentiated approach designed to address limitations patients and clinicians know all too well."

A New Mechanism for a Persistent Problem

For decades, the primary pharmacological tools for anxiety have been selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines. While effective for many, these treatments are hampered by significant limitations: SSRIs can take four to six weeks to work and may initially worsen anxiety, while benzodiazepines carry risks of sedation, cognitive impairment, and dependence.

Sensorium's SNTX-2643 aims to break this mold. The compound is a first-in-class, state-selective serotonin transporter (SERT) modulator. Unlike traditional SSRIs that bind directly to the main (orthosteric) site of the serotonin transporter, SNTX-2643 is designed to bind to a different (allosteric) site. This unique mechanism is intended to modulate SERT activity in a more nuanced way, potentially leading to a rapid onset of anti-anxiety effects without the drawbacks of existing therapies.

The company's preclinical data, to be shared at ASCP, reportedly reveals a distinct downstream molecular signature for SNTX-2643 compared to the common SSRI fluoxetine, providing early evidence that its unique mechanism translates to different biological effects at the cellular level. The goal is a treatment that acts quickly, has fewer off-target effects, and avoids the sedation associated with benzodiazepines.

"There remains a substantial unmet need for anxiety treatments that can address limitations of current options, including delayed onset, tolerability burden, sedation, and dependence concerns," said Dr. Andrew Cutler, a Clinical Professor of Psychiatry at SUNY Upstate Medical University and a new member of Sensorium's Clinical Advisory Board. "SNTX-2643's differentiated mechanism... creates an exciting opportunity to deliver a new treatment to help the millions of people and their families suffering with anxiety."

Charting the Path with Rigorous Clinical Design

To evaluate SNTX-2643's potential in humans, Sensorium has initiated a Phase 1a study in healthy adult volunteers. The study design, a focus of the ASCP presentation, underscores the company's disciplined approach. It is a randomized, double-blind, placebo-controlled trial—the gold standard for minimizing bias in clinical research.

The study is designed to primarily assess the safety and tolerability of single escalating doses of the drug. Secondary goals include characterizing its pharmacokinetic profile (how the body absorbs, distributes, and clears the drug) and its pharmacodynamic effects (what the drug does to the body).

Notably, the trial includes a target engagement cohort that will use quantitative electroencephalography (qEEG) to measure the drug's effects on brain activity. This includes using an anxiety-inducing stimulus to directly observe if SNTX-2643 can modulate the brain's response to stress, providing early signs of efficacy. Topline results from this foundational study are anticipated in the second half of 2026 and will be crucial for planning future patient trials.

New Leadership to Steer Clinical Development

Guiding this critical clinical work will be Dr. Cole Brown, Sensorium's newly appointed Chief Medical Officer. Dr. Brown brings nearly two decades of experience in drug development, joining the company from Sage Therapeutics, a leader in CNS disorders known for its work in depression. His extensive background spans clinical development, medical affairs, and regulatory strategy, including contributions to nearly a dozen drug launches throughout his career.

His experience at a company focused on novel mechanisms for psychiatric conditions makes him a key strategic addition as Sensorium moves its lead asset into the clinic. Dr. Brown will oversee the clinical development across Sensorium's entire pipeline.

"Sensorium has built a disciplined clinical development organization around a discovery platform designed to generate differentiated CNS medicines," said Dr. Brown. "SNTX-2643 is a thoughtfully designed program around new pharmacology for a well-validated target, and I look forward to advancing it through Phase 1 and into patient studies with the rigor this program deserves."

Assembling a 'Who's Who' of Psychiatric Expertise

Further bolstering its scientific and clinical prowess, Sensorium has formed a Clinical Advisory Board populated by some of the most respected figures in psychiatry and neuroscience. The founding members include department chairs and distinguished professors from institutions like Massachusetts General Hospital, Duke University, University of California San Diego, and the University of Texas at Austin's Dell Medical School.

The board features prominent names such as Dr. Charles B. Nemeroff, a leading expert on the neurobiology of mood and anxiety disorders, and Dr. Maurizio Fava, Chair of the Psychiatry Department at Massachusetts General Brigham. This assembly of academic and clinical leaders will provide critical guidance on Sensorium's development programs, ensuring its innovative science is grounded in sound clinical strategy and a deep understanding of patient needs.

Combined, the presentation at a major scientific conference, the advancement of a novel compound into the clinic, and the strategic fortification of its leadership team signal a period of significant momentum for Sensorium. With its proprietary SensAI discovery platform also generating preclinical programs for treatment-resistant epilepsy and cognitive enhancement, the company is methodically building a pipeline aimed at addressing some of the most challenging disorders of the central nervous system.